From the publishers of JADPRO

Metastatic Triple-Negative Breast Cancer Resource Center

Advertisement

Datopotamab Deruxtecan in Advanced/Metastatic HER2- Breast Cancer: Results From the Phase 1 TROPION-Pantumor01 Study

Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer, according to early findings from the phase I TROPION-PanTumor01 trial presented during the 2021 San Antonio Breast Cancer Symposium by Ian E. Krop, MD, PhD.

2021 San Antonio Breast Cancer Symposium
Advertisement
News & Literature Highlights
Advertisement
Advertisement